Marshall B. Lucas

1 presentation

• W17. LONG-TERM SAFETY AND TOLERABILITY OF CARIPRAZINE IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER, BIPOLAR I DISORDER OR SCHIZOPHRENIA: FINAL RESULTS FROM AN OPEN-LABEL STUDY

  2026 ASCP Annual Meeting